cetuximab,pembrolizumab,evorpacept
merck,eli lilly,alx oncology's,alx oncology
[]
. s dr. howard hochster ( ), dr. patrick boland ( ) &amp; colleagues present trial in progress: a phase ii study (w/ safety run-in) of evorpacept (alx148), cetuximab, and pembrolizumab in patients... #gi23 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.